Close Menu

NEW YORK – The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended approval for tucatinib (Seagen's Tukysa) in combination with trastuzumab (Genentech's Herceptin) and chemotherapy for HER2-positive locally advanced or metastatic breast cancer patients previously treated with two prior anti-HER2 treatment regimens.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.